BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 18287268)

  • 1. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
    Peterson LM; Mankoff DA; Lawton T; Yagle K; Schubert EK; Stekhova S; Gown A; Link JM; Tewson T; Krohn KA
    J Nucl Med; 2008 Mar; 49(3):367-74. PubMed ID: 18287268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
    Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
    J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
    Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
    Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
    Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
    J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
    Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
    Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
    Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
    Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[
    Katzenellenbogen JA
    Nucl Med Biol; 2021 Jan; 92():24-37. PubMed ID: 32229068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice.
    Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F
    Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.
    Peterson LM; Kurland BF; Link JM; Schubert EK; Stekhova S; Linden HM; Mankoff DA
    Nucl Med Biol; 2011 Oct; 38(7):969-78. PubMed ID: 21982568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
    van Kruchten M; Glaudemans AW; de Vries EF; Beets-Tan RG; Schröder CP; Dierckx RA; de Vries EG; Hospers GA
    J Nucl Med; 2012 Feb; 53(2):182-90. PubMed ID: 22241912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.
    Munter-Young R; Fuentes-Alburo A; DiGregorio N; Neeser K; Gultyaev D
    PLoS One; 2024; 19(5):e0302486. PubMed ID: 38743917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
    Kurland BF; Peterson LM; Lee JH; Linden HM; Schubert EK; Dunnwald LK; Link JM; Krohn KA; Mankoff DA
    J Nucl Med; 2011 Oct; 52(10):1541-9. PubMed ID: 21903739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-Fluoroestradiol Tumor Uptake Is Influenced by Structural Components in Breast Cancer.
    Takahashi M; Maeda H; Tsujikawa T; Kono H; Mori T; Kiyono Y; Okazawa H; Noriki S; Imamura Y; Goi T
    Clin Nucl Med; 2021 Nov; 46(11):884-889. PubMed ID: 34319950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[
    Mankoff D; Balogová S; Dunnwald L; Dehdashti F; DeVries E; Evangelista L; Van Kruchten M; Vaz SC; Fowler A; Linden H; Ulaner GA
    J Nucl Med; 2024 Feb; 65(2):221-223. PubMed ID: 38071554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
    Linden HM; Stekhova SA; Link JM; Gralow JR; Livingston RB; Ellis GK; Petra PH; Peterson LM; Schubert EK; Dunnwald LK; Krohn KA; Mankoff DA
    J Clin Oncol; 2006 Jun; 24(18):2793-9. PubMed ID: 16682724
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Kumar M; Salem K; Michel C; Jeffery JJ; Yan Y; Fowler AM
    J Nucl Med; 2019 Sep; 60(9):1247-1252. PubMed ID: 30850489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging.
    Aliaga A; Rousseau JA; Ouellette R; Cadorette J; van Lier JE; Lecomte R; Bénard F
    Nucl Med Biol; 2004 Aug; 31(6):761-70. PubMed ID: 15246367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.
    Liao GJ; Clark AS; Schubert EK; Mankoff DA
    J Nucl Med; 2016 Aug; 57(8):1269-75. PubMed ID: 27307345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
    van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
    J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.